In addition, combining mTOR and CDK8/19 inhibitors elicited transcriptional changes that were specific to the drug combination, such as upregulation of the IFNα/γ pathways in tumor cells and of extracellular proteins associated with tumor suppression (e.g., Lrp1b) or inhibition of angiogenesis (Tnmd) in stromal cells. Here, MTOR is linked to neoplasm.